Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK 399.80
+4.00 (1.01%)
At close: Feb 10, 2026
STO:SOBI Revenue
In the year 2025, Swedish Orphan Biovitrum AB had annual revenue of 28.24B SEK with 8.50% growth. Swedish Orphan Biovitrum AB had revenue of 7.82B in the quarter ending December 31, 2025, with 5.19% growth.
Revenue
28.24B
Revenue Growth
+8.50%
P/S Ratio
4.84
Revenue / Employee
14.96M
Employees
1,888
Market Cap
136.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.24B | 2.21B | 8.50% |
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.46B |
| EQL Pharma AB | 425.75M |
| Enzymatica AB | 52.73M |
| Cinclus Pharma Holding AB | 48.42M |
| Cereno Scientific AB | 46.66M |
| Nanexa AB | 31.92M |
| Orexo AB | 26.00M |
| Moberg Pharma AB | 12.50M |
Swedish Orphan Biovitrum AB News
- 5 days ago - Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Swedish Orphan Biovitrum AB (publ) 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 5 days ago - Swedish Orphan Biovitrum AB reports Q4 results - Seeking Alpha
- 25 days ago - European Commission Approves Sobi's Aspaveli for Rare Kidney Diseases - GuruFocus
- 26 days ago - SOBI: 2025 Revenue, Adj. EBITA Margin Higher Than Prior Guidance - Nasdaq
- 27 days ago - Swedish Orphan Biovitrum AB (publ) (SWOBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Sobi Reports Positive Phase 2a EMBRACE Study Results For Gamifant In IFN?-Driven Sepsis - Nasdaq
- 2 months ago - Swedish Orphan Biovitrum AB (publ) (SWOBY) M&A Call Transcript - Seeking Alpha